See the DrugPatentWatch profile for Takhzyro
When does the Takhzyro patent expire?
Takhzyro (lanadelumab) has a complex U.S. patent and exclusivity landscape, with multiple patents and regulatory exclusivities that can affect when generic or biosimilar versions are allowed to enter.
For the most up-to-date patent-expiration and exclusivity timing, DrugPatentWatch tracks the relevant Takhzyro patents and projected dates. You can check the current listing here: DrugPatentWatch – Takhzyro (lanadelumab) patent expiration.
What patents usually control Takhzyro exclusivity (not just one “main” patent)?
Even when one key patent nears expiration, later-expiring patents (for example, formulation, manufacturing process, or specific claims around the biologic) can extend market protection. That’s why Takhzyro exclusivity is often determined by the latest relevant patent(s) and any additional granted exclusivities, not a single date.
DrugPatentWatch’s patent-by-patent breakdown is designed to show which specific patents are still in force and when they expire. [1]
Can biosimilars enter right when a patent expires?
In biologics, biosimilar entry depends on more than the earliest patent expiration date. A biosimilar applicant may need to wait until patents covering the product are no longer enforceable, or until any relevant exclusivity periods end. If patents are still active, biosimilar launch can be delayed even if some earlier patents expire.
Check DrugPatentWatch for Takhzyro’s “potential/earliest” and “likely” protection end dates based on the remaining listed patents. [1]
Why timing searches differ from one site to another
Patent expiration estimates can differ because:
- multiple patents with different expiration dates may apply,
- some patents may be listed but later narrowed/invalidated (or vice versa),
- regulatory exclusivities can add additional protection beyond patent terms.
DrugPatentWatch is commonly used to reconcile those elements for a “market protection” view. [1]
Source
[1] https://www.drugpatentwatch.com/p/takhzyro (DrugPatentWatch – Takhzyro / lanadelumab patent expiration)